AMERICAN VANGUARD CORPAVD
時価総額
$1.1億
PER
農薬・特殊化学品の有力企業。天然油由来の生物系農薬とIPライセンスを展開。主要株主にBlackRock6.03%とVanguard5.36%、2023年10月にPunto Verdeを買収。米国・メキシコ・ブラジル・豪州など45カ国で展開。
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Cash | 35 | 38 | 7 | - | - | - | - | - | - | - | - | - | 11 | 13 |
| Accounts Receivable, after Allowance for Credit Loss, Current | 69 | 76 | 74 | 86 | 73 | 84 | 103 | 123 | 136 | 130 | 149 | 156 | 183 | 170 |
| Other | - | - | - | 2 | 3 | 3 | 7 | 11 | 17 | 8 | 10 | 10 | 8 | 5 |
| Total receivables, net | - | - | - | - | - | - | - | - | - | 138 | 159 | 166 | 191 | 174 |
| Inventories | 71 | 88 | 140 | 166 | 136 | 121 | 123 | 160 | 163 | 164 | 154 | 184 | 220 | 179 |
| Prepaid expenses | 2 | - | - | - | - | 11 | 11 | 10 | 10 | 10 | 12 | 16 | 6 | 8 |
| Income taxes receivable | 0 | - | 10 | 6 | 0 | - | - | - | 3 | 3 | - | 2 | 4 | 5 |
| Total current assets | 178 | 222 | 250 | 287 | 237 | 227 | 255 | 310 | 336 | 332 | 342 | 389 | 432 | 379 |
| Property, plant and equipment, net | 39 | 46 | 52 | 50 | 48 | 50 | 49 | 49 | 57 | 65 | 66 | 71 | 75 | 58 |
| Operating lease right-of-use assets | - | - | - | - | - | - | - | - | 11 | 12 | 25 | 24 | 22 | 20 |
| Intangible assets, net | - | - | - | 100 | 129 | 121 | 181 | 187 | 198 | 198 | 198 | 185 | 173 | 150 |
| Goodwill | - | - | - | - | - | - | 22 | 26 | 47 | 52 | 46 | 47 | 51 | 20 |
| Deferred income tax assets | - | - | - | - | - | - | - | - | - | 3 | 0 | 0 | 3 | 1 |
| Other assets | 5 | 18 | 38 | 36 | 30 | 31 | 28 | 22 | 21 | 19 | 16 | 11 | 12 | 8 |
| Total assets | 339 | 400 | 447 | 473 | 444 | 430 | 536 | 594 | 670 | 680 | 694 | 726 | 768 | 637 |
| Accounts payable | 23 | 33 | 41 | 20 | 15 | 24 | 54 | 67 | 65 | 59 | 67 | 69 | 69 | 69 |
| Customer prepayments | - | - | - | - | - | - | - | - | - | - | - | 111 | 66 | 53 |
| Accrued program costs | 26 | 32 | 54 | 53 | 44 | 43 | 39 | 37 | 48 | 45 | 63 | 61 | 68 | 69 |
| Accrued expenses and other payables | 7 | 9 | 10 | 6 | 7 | 12 | 12 | 16 | 13 | 16 | 21 | 21 | 16 | 32 |
| Operating Lease, Liability, Current | - | - | - | - | - | - | - | - | 5 | 4 | 5 | 5 | 6 | 6 |
| Income taxes payable | - | - | - | - | - | - | - | - | - | - | 3 | - | 6 | 3 |
| Total current liabilities | 79 | 114 | 110 | 81 | 76 | 97 | 126 | 146 | 139 | 171 | 223 | 267 | 230 | 232 |
| Long-term debt | - | 36 | 52 | 99 | 68 | 41 | 77 | 97 | 149 | 107 | 52 | 51 | 139 | 147 |
| Operating lease liabilities, long-term | - | - | - | - | - | - | - | - | 7 | 8 | 21 | 19 | 17 | 14 |
| Deferred income tax liabilities | - | - | - | - | - | - | - | - | - | 24 | 20 | 15 | 8 | 8 |
| Other liabilities | 52 | - | - | 3 | 3 | 3 | 10 | 7 | 13 | 9 | 5 | 4 | 3 | 2 |
| Total liabilities | 152 | 174 | 190 | 212 | 175 | 148 | 230 | 264 | 326 | 320 | 321 | 356 | 398 | 404 |
| Common Stock, Value, Issued | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Additional paid-in capital | - | - | - | - | 69 | 72 | 76 | 83 | 91 | 97 | 101 | 106 | 111 | 115 |
| Accumulated other comprehensive loss | -2 | -2 | -1 | -2 | -4 | -5 | -5 | -5 | -6 | -9 | -14 | -12 | -6 | -19 |
| Retained earnings | 144 | 174 | 202 | 202 | 209 | 220 | 239 | 263 | 274 | 288 | 304 | 329 | 333 | 205 |
| Total stockholders' equity including treasury stock | 190 | 230 | 265 | 270 | 277 | 290 | 313 | 345 | 362 | 379 | 395 | 426 | 441 | 304 |
| Less treasury stock at cost, 5,915,182 shares in 2024 and 5,915,182 in 2023 | 3 | 5 | 7 | 8 | 8 | 8 | 8 | 16 | 18 | 18 | 23 | 56 | 71 | 71 |
| Total stockholders’ equity | - | 225 | 258 | 261 | 268 | 282 | 305 | 329 | 344 | 361 | 373 | 370 | 370 | 233 |
| Total liabilities and stockholders’ equity | 339 | 400 | 447 | 473 | 444 | 430 | 536 | 594 | 670 | 680 | 694 | 726 | 768 | 637 |